8-K: AEON Biopharma Faces NYSE American Delisting Notice Due to Stockholders' Equity Deficit

AEON Biopharma received a notice from NYSE American regarding non-compliance with continued listing standards due to a stockholders' equity deficit.

Summary

• AEON Biopharma received a non-compliance notice from the NYSE American on February 3, 2025, because its stockholders' equity fell below the required $2.0 million minimum.
• As of September 30, 2024, AEON reported a stockholders' deficit of $32.1 million.
• The company also had losses in the two most recent fiscal years ended December 31, 2023.
• AEON must submit a plan by March 5, 2025, to regain compliance by August 3, 2026.
• Failure to submit an acceptable plan or regain compliance could lead to delisting proceedings.
• The company intends to submit a plan to address the non-compliance.
• The notice does not immediately affect the listing of AEON's common stock, but it will have an added designation of .BC to indicate the status of the Common Stock are below compliance.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the company's financial difficulties. While the company intends to address the issue, there is no guarantee of success.

Positives

• The notice has no immediate effect on the listing of AEON's shares.
• AEON intends to submit a plan to regain compliance with NYSE American listing standards.
• The company has 18 months to regain compliance.

Negatives

• AEON Biopharma is not in compliance with NYSE American continued listing standards.
• The company has a stockholders' deficit of $32.1 million.
• There is no assurance that the company will be able to regain compliance.

Risks

• Failure to submit an acceptable plan to the NYSE American.
• Inability to regain compliance with the minimum stockholders' equity requirement by August 3, 2026.
• Potential delisting from the NYSE American.
• The company's ability to raise financing in the future.

Future Outlook

The company intends to submit a plan to regain compliance with NYSE American listing standards, but there is no guarantee of success.

Management Comments

• The Company intends to fully comply with NYSE American's requests and will submit its Plan accordingly.

Industry Context

AEON Biopharma is a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex, ABP-450, for medical conditions, similar to Evolus' Jeuveau for cosmetic indications; the delisting notice raises concerns about its financial stability and ability to continue operations.

Comparison to Industry Standards

• Other biopharmaceutical companies facing financial difficulties have explored options such as reverse mergers, asset sales, or significant restructuring to maintain their listing status.
• Companies like Evolus, which markets a similar product (Jeuveau), maintain a stronger financial position, highlighting the competitive pressures in the botulinum toxin market.
• The $2.0 million minimum stockholders' equity requirement is a standard benchmark for continued listing on exchanges like NYSE American, and failure to meet this threshold is a common reason for delisting notices.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment.
• Employees may experience uncertainty regarding job security.
• The company's ability to develop and commercialize ABP-450 could be affected.

Next Steps

• AEON Biopharma must submit a plan to the NYSE American by March 5, 2025.
• The company must regain compliance with NYSE American listing standards by August 3, 2026.
• The NYSE American will conduct periodic reviews to monitor compliance with the plan.

Key Dates